Lineage Cell Therapeutics Inc
XBER:BT3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lineage Cell Therapeutics Inc
XBER:BT3
|
US |
|
CareCloud Inc
F:MTB0
|
US |
|
Southwest Gas Holdings Inc
F:SZR
|
US |
|
S
|
Stockland Corporation Ltd
F:LN1
|
AU |
|
MillerKnoll Inc
F:MHR
|
US |
|
S
|
Sankyu Inc
TSE:9065
|
JP |
|
W
|
Willscot Mobile Mini Holdings Corp
SWB:WS11
|
US |
|
Globant SA
NYSE:GLOB
|
LU |
Wall St Price Targets
BT3 Price Targets Summary
Lineage Cell Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BT3 is 5.41 EUR with a low forecast of 2.92 EUR and a high forecast of 9.12 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BT3's stock price target?
Price Target
5.41
EUR
According to Wall Street analysts, the average 1-year price target for BT3 is 5.41 EUR with a low forecast of 2.92 EUR and a high forecast of 9.12 EUR.
What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 74%.
What is the Gross Profit forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 74%.
